Iovance Biotherapeutics to Webcast Analyst Day on Wednesday, December 13, 2017
December 07 2017 - 8:00AM
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced
that it will webcast its Analyst Day on Wednesday, December 13,
2017 from 9:00 a.m. to 12:00 p.m. ET in New York, NY.
The event will highlight Iovance’s lead clinical programs,
LN-144 for the treatment of metastatic melanoma, LN-145 for
recurrent and/or metastatic squamous cell carcinoma of the head and
neck, and LN-145 for recurrent, metastatic or persistent cervical
cancer. In addition, Iovance will discuss the expanding
clinical pipeline, strategic collaborations and manufacturing plan
for upcoming clinical trials.
A live webcast of the presentation can be accessed on the
investor page of Iovance Biotherapeutics’ website at
http://www.iovance.com. A replay of the webcast will be archived on
Iovance Biotherapeutics’ website for 30 days following the
presentation.
About Iovance Biotherapeutics, Inc. Iovance
Biotherapeutics, Inc. is a clinical-stage biotechnology
company focused on the development of cancer immunotherapy products
for the treatment of various cancers. The Company's lead product
candidate is an adoptive cell therapy using tumor-infiltrating
lymphocyte (TIL) technology being investigated for the treatment of
patients with metastatic melanoma, recurrent and/or metastatic
squamous cell carcinoma of the head and neck and recurrent,
metastatic or persistent cervical cancer. For more information,
please visit http://www.iovance.com.
Investor Relations Contact: Sarah McCabe Stern
Investor Relations, Inc. 212-362-1200 sarah@sternir.com
Media Contact: Evan Smith FTI Consulting
212-850-5622 evan.smith@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024